Hwail Pharmaceutical Co.Ltd (061250) — Capital Reinvestment Ratio
Hwail Pharmaceutical Co.Ltd (061250) has a Capital Reinvestment Ratio of 0.20x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩6.82 Billion) in capital expenditures (₩1.39 Billion). Check 061250 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hwail Pharmaceutical Co.Ltd Capital Reinvestment Ratio (2011–2024)
This chart tracks Hwail Pharmaceutical Co.Ltd's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see Hwail Pharmaceutical Co.Ltd (061250) cash flow conversion.
Annual Capital Reinvestment Ratio for Hwail Pharmaceutical Co.Ltd (2011–2024)
Year-by-year Capital Reinvestment Ratio for Hwail Pharmaceutical Co.Ltd from 2011 to 2024. See 061250 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.98x | ₩11.63 Billion | ₩34.63 Billion | ▲ +894.9% |
| 2023 | 0.30x | ₩7.02 Billion | ₩2.10 Billion | ▲ +143.3% |
| 2021 | 0.12x | ₩20.09 Billion | ₩2.47 Billion | ▼ -58.2% |
| 2019 | 0.29x | ₩3.69 Billion | ₩1.09 Billion | ▲ +36.1% |
| 2018 | 0.22x | ₩7.17 Billion | ₩1.55 Billion | ▲ +250.9% |
| 2017 | 0.06x | ₩8.34 Billion | ₩513.62 Million | ▲ +42.9% |
| 2016 | 0.04x | ₩9.58 Billion | ₩413.00 Million | ▼ -96.7% |
| 2013 | 1.32x | ₩6.97 Billion | ₩9.18 Billion | ▼ -82.9% |
| 2012 | 7.69x | ₩1.00 Billion | ₩7.72 Billion | ▲ +1034.5% |
| 2011 | 0.68x | ₩7.86 Billion | ₩5.32 Billion | — |